Cubicin Lyophilisate For Solution For Injection 500Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Cubicin: Lyophilisate for solution for injection (500mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

DAPTOMYCIN (DAP toe MYE sin) is a lipopeptide antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections.

In-Depth Information

Cubicin 500mg Powder for Injection

NDC: 679190011
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Bacteremia, Endocarditis, Skin And Skin Structure Infections

Sometimes used for but not FDA approved for the following conditions:
Orthopedic Device-related Infection, Bone And Joint Infections, Vancomycin-resistant Enterococci (VRE), Infectious Arthritis, Osteomyelitis

Storage Information
Avoid exposure to heat
Refrigerate (between 36 and 46 degrees F)
Cubicin 500mg Powder for Injection

Reported Side Effects for Cubicin 500mg Powder for Injection

Balance Problems Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Yellow Skin Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
High White Blood Cells Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Muscle Cramps Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Muscle Disease Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Metallic Taste Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Eosinophilia Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Flushing Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Eye Irritation Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Paresthesias Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Weakness Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Joint Pain Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Eczema Vaccinatum Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Tired Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Low Magnesium Levels Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
High Platelet Count Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Low Platelet Count Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Mouth Ulcers Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Muscle Pain Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Low Prothrombin Level Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Shortness Of Breath Incidence:
2.1%*
Severity: MODERATE
Onset: EARLY
Lightheadedness Incidence:
2.2%*
Severity: MILD
Onset: EARLY
Infection Incidence:
2.4-5.0%*
Severity: MILD
Onset: DELAYED
Low Blood Pressure Incidence:
2.4%*
Severity: MODERATE
Onset: RAPID
Elevated Hepatic Enzymes Incidence:
3.0%*
Severity: MODERATE
Onset: DELAYED
Skin Rash Incidence:
4.3%*
Severity: MILD
Onset: EARLY
Excessive Sweating Incidence:
5.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
5.2%*
Severity: MILD
Onset: EARLY
Headache Incidence:
5.4%*
Severity: MILD
Onset: EARLY
Itching Incidence:
6.0%*
Severity: MILD
Onset: RAPID
Stomach Pain Incidence:
6.0%*
Severity: MILD
Onset: EARLY
High Blood Pressure Incidence:
6.0%*
Severity: MODERATE
Onset: EARLY
Swelling Incidence:
7.0%*
Severity: MODERATE
Onset: DELAYED
Chest Pain Incidence:
7.0%*
Severity: MODERATE
Onset: EARLY
Inability To Sleep Incidence:
9.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Cubicin

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5